Stifel analyst Alex Thompson downgraded Chinook Therapeutics (KDNY) to Hold from Buy with a price target of $41, down from $43, after Novartis (NVS) agreed to acquire Chinook for $3.2B upfront plus contingent value rights, or CVRs, worth up to $320M. The firm has updated its model to reflect the terms of the deal, including the CVRs, risk adjusted and discounted to their respective timelines.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KDNY:
- Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
- Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
- KDNY Upcoming Earnings Report: What to Expect?
- Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
